Fulcrum Therapeutics (FULC) Capital Expenditures (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Capital Expenditures of $108000.0 for Q2 2026, up 66.15% year-over-year from $65000.0 in Q2 2025, and up 1250.0% quarter-over-quarter from $8000.0 in Q1 2026.
Fulcrum Therapeutics (FULC) Capital Expenditures (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Capital Expenditures for 9 consecutive years, with $108000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures rose 66.15% year-over-year to $108000.0; the TTM figure through Jun 2026 stood at $365000.0 (up 15.87% YoY), while the FY2025 annual figure was $314000.0, up 12.95% from the prior year.
- Capital Expenditures advanced to $108000.0 in Q2 2026 per FULC's latest filing, from $8000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $847000.0 in Q1 2022 and bottomed at $8000.0 in Q1 2026.
- Historically, Capital Expenditures has averaged $198687.5 across 5 years, with a median of $112000.0 in 2022.
- Annual changes were most pronounced in 2022 — Capital Expenditures surged 223.28% — and 2024, when it slumped 83.63%.
- Fulcrum Therapeutics' Capital Expenditures stood at $116000.0 in 2022, then sank by 33.62% to $77000.0 in 2023, then climbed by 27.27% to $98000.0 in 2024, then surged by 58.16% to $155000.0 in 2025, then sank by 30.32% to $108000.0 in 2026.
- Business Quant data shows FULC's Capital Expenditures at $108000.0 in Q2 2026, $8000.0 in Q1 2026, and $155000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 108,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108,000.00 |
| Jun 30, 2026 | 108,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Mar 31, 2026 | 8,000.00 |
| Dec 31, 2025 | 159,000.00 |
| Dec 31, 2025 | 159,000.00 |
| Sep 30, 2025 | 155,000.00 |
| Sep 30, 2025 | 155,000.00 |
| Dec 31, 2024 | 231,000.00 |
| Dec 31, 2024 | 231,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Sep 30, 2024 | 28,000.00 |
| Jun 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -9,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Mar 31, 2024 | 28,000.00 |
| Dec 31, 2023 | 508,000.00 |
| Dec 31, 2023 | 508,000.00 |
| Sep 30, 2023 | -47,000.00 |
| Sep 30, 2023 | -47,000.00 |